#	Pagina
attuale pagina	/open-h2020/projects/226446/index.html
-1	/open-h2020/projects/218986/index.html

Opendata, web and dolomites

SMA-TB SIGNED

A novel Stratified Medicine Algorithm to predict treatment responses to host-directed therapy in TB patients.

Total Cost €

EC-Contrib. €

Partnership

Views

SMA-TB project word cloud

Explore the words cloud of the SMA-TB project. It provides you a very rough idea of what is the project "SMA-TB" about.

prevalence generate clinically standard lung hyperinflammation inflammatory reduce infective sma resistant poses therapeutic resistance clinical aspirin intervention mdr regimen validate physicians effect stratifying strain generating world decrease directed relevance adjunct cure host tissue individualized predicting responsible susceptibility infectious ct biomarkers algorithm anti sensitive permanent pathogen bad integrating severity outcomes protocol length disease highest personalized chronic benefit risk treatment predict tremendous personalize tb mathematical course drug worse sequelae potentially add stratify stages damage costly hdt therapies science medical network health thanks life data region patients trials tuberculosis forms medicine faster ds shorten therapy threatening differ

Project "SMA-TB" data sheet

The following table provides information about the project.

Coordinator	INSTITUT DE INVESTIGACIO EN CIENCIES DE LA SALUT GERMANS TRIAS I PUJOL Organization address address: CTRA DE CANYET S/N city: BADALONA BARCELONA postcode: 8916 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Spain [ES]
Total cost	6˙388˙104 €
EC max contribution	6˙388˙104 € (100%)
Programme	1. H2020-EU.3.1.3. (Treating and managing disease)
Code Call	H2020-SC1-2019-Two-Stage-RTD
Funding Scheme	RIA
Starting year	2020
Duration (year-month-day)	from 2020-01-01 to 2024-06-30

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	INSTITUT DE INVESTIGACIO EN CIENCIES DE LA SALUT GERMANS TRIAS I PUJOL INSTITUT DE INVESTIGACIO EN CIENCIES DE LA SALUT GERMANS TRIAS I PUJOL Organization address address: CTRA DE CANYET S/N city: BADALONA BARCELONA postcode: 8916 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	ES (BADALONA BARCELONA)	coordinator	1˙632˙750.00
2	WITS HEALTH CONSORTIUM (PTY) LTD WITS HEALTH CONSORTIUM (PTY) LTD Organization address address: Princess of Wales Terrace, Parktown, 31 city: Johannesburg postcode: 2193 website: www.witshealth.co.za contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	ZA (Johannesburg)	participant	1˙107˙324.00
3	OSLO UNIVERSITETSSYKEHUS HF OSLO UNIVERSITETSSYKEHUS HF Organization address address: KIRKEVEIEN 166 TARNBYGGET city: OSLO postcode: 450 website: http://www.oslo-universitetssykehus.no contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NO (OSLO)	participant	840˙125.00
4	CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS Organization address address: RUE MICHEL ANGE 3 city: PARIS postcode: 75794 website: www.cnrs.fr contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FR (PARIS)	participant	656˙910.00
5	NATIONAL CENTER FOR TUBERCULOSIS AND LUNG DISEASES JSC NATIONAL CENTER FOR TUBERCULOSIS AND LUNG DISEASES JSC Organization address address: 8 ADJARA city: TBILISI postcode: 101 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	GE (TBILISI)	participant	646˙016.00
6	ACADEMISCH ZIEKENHUIS LEIDEN ACADEMISCH ZIEKENHUIS LEIDEN Organization address address: ALBINUSDREEF 2 city: LEIDEN postcode: 2333 ZA website: www.lumc.nl contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NL (LEIDEN)	participant	612˙563.00
7	ANAXOMICS BIOTECH SL ANAXOMICS BIOTECH SL Organization address address: CALLE DIPUTACIO 237, P 1 PTA 1 city: BARCELONA postcode: 8007 website: www.anaxomics.com contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	ES (BARCELONA)	participant	428˙250.00
8	TES2A EUROPE CONSULTING AND BUSINESS DEVELOPMENT SL TES2A EUROPE CONSULTING AND BUSINESS DEVELOPMENT SL Organization address address: RBLA LLUIS COMPANYS 18 (3,1) city: SANT QUIRZE DEL VALLES postcode: 8192 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	ES (SANT QUIRZE DEL VALLES)	participant	339˙260.00
9	LIONEX GMBH LIONEX GMBH Organization address address: Salzdahlumer Strasse 196 city: BRAUNSCHWEIG postcode: 38126 website: www.lionex.de contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (BRAUNSCHWEIG)	participant	124˙905.00

Map

Project objective

Tuberculosis (TB) is a chronic, life-threatening infectious disease which poses a tremendous challenge for physicians, researchers and Health Systems, which treatment is long, based only on the drug susceptibility of the responsible infective strain and very costly in drug-resistant cases (MDR-TB). The European Region still has the highest prevalence of MDR-TB in the world. Host-Directed Therapies (HDT) have been recently proposed to shorten treatment length and by to improve the patients’ outcomes while not increasing the risk of generating drug resistance. As hyperinflammation is responsible of the lung damage associated to patients’ worse outcomes and sequelae, one of the approaches is to add an HDT with anti-inflammatory effect to the current drug regimen to cure the patients faster while having less permanent lung damage. Because TB has a wide range of clinical forms and severity stages, any therapeutic regimen needs to be studied in clinical trials (CT) as its benefit might differ among patients. No individualized personalized medicine is possible without stratifying the patients by integrating pathogen and host factors that will predict the course of the disease and the response to the intervention. SMA-TB objectives are: • To evaluate in a CT the potential impact of aspirin (an anti-inflammatory HDT) as adjunct to standard therapy for drug sensitive (DS-) and MDR-TB. This potentially will reduce tissue damage, decrease the length of the treatment and the risk of bad outcomes. • To identify and clinically validate host and pathogen biomarkers for further selection according to their relevance in terms of their ability to predict TB course and outcomes and response to treatment thanks to data science protocol. • To generate a medical algorithm to stratify patients using network-based mathematical modelling for predicting the course of the disease and its response to the intervention, to be applied during clinical management to improve and personalize TB

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SMA-TB" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SMA-TB" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

TT4CL (2019)

Clinical development of oral oleylphosphocholine as a new drug for the treatment of Old World Cutaneous Leishmaniasis

MISTRAL (2020)

Microbiome-based stratification of individuals at risk of HIV-1 acquisition, chronic clinical complications,antimicrobial drug resistance,and unresponsiveness to therapeutic HIV-1 vaccination